Literature DB >> 7108282

The arabinitol appearance rate in laboratory animals and humans: estimation from the arabinitol/creatine ratio and relevance to the diagnosis of candidiasis.

B Wong, E M Bernard, J W Gold, D Fong, D Armstrong.   

Abstract

The effects of renal function on serum concentrations of the candidal metabolite arabinitol were studied by examining the accumulation and elimination of arabinitol in animals and humans. Serum concentrations of arabinitol rose sharply and in direct proportion to creatine concentrations after nephrectomy in rats. The serum half-life of exogenous arabinitol was 20.8 hr in anephric rats but only 0.62 hr in sham-nephrectomized control animals. The mean +/- SD apparent space of distribution of arabinitol was 419 +/- 26 ml/kg. The fraction of exogenously administered arabinitol recovered in the urine was 0.73 +/- 0.13 in uremic rats, 0.85 +/- 0.28 in control rats, and 0.95 +/- 0.10 in normal dogs. The arabinitol/creatinine clearance ratio was 0.99 +/- 0.08 in normal dogs and 0.99 +/- 0.25 in 22 critically ill patients with cancer. Thus arabinitol is eliminated by nearly quantitative urinary excretion and its cleared at virtually the same rate as creatinine. Therefore, the rate of arabinitol appearance in the body from any source equals the urinary arabinitol excretion rate and is directly proportional to the concentration ratio of arabinitol to creatinine in serum or urine.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7108282     DOI: 10.1093/infdis/146.3.353

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  21 in total

1.  A rapid, automated enzymatic fluorometric assay for determination of D-arabinitol in serum.

Authors:  S F Yeo; Y Zhang; D Schafer; S Campbell; B Wong
Journal:  J Clin Microbiol       Date:  2000-04       Impact factor: 5.948

2.  Comparison of enzyme immunoassay and gas-liquid chromatography for the rapid diagnosis of invasive candidiasis in cancer patients.

Authors:  L de Repentigny; L D Marr; J W Keller; A W Carter; R J Kuykendall; L Kaufman; E Reiss
Journal:  J Clin Microbiol       Date:  1985-06       Impact factor: 5.948

3.  Comparison of serum mannan, arabinitol, and mannose in experimental disseminated candidiasis.

Authors:  L de Repentigny; R J Kuykendall; F W Chandler; J R Broderson; E Reiss
Journal:  J Clin Microbiol       Date:  1984-06       Impact factor: 5.948

4.  Clinical correlations of serial quantitative blood cultures determined by lysis-centrifugation in patients with persistent septicemia.

Authors:  E Whimbey; B Wong; T E Kiehn; D Armstrong
Journal:  J Clin Microbiol       Date:  1984-06       Impact factor: 5.948

Review 5.  New developments in the diagnosis of opportunistic fungal infection.

Authors:  V Hopwood; D W Warnock
Journal:  Eur J Clin Microbiol       Date:  1986-08       Impact factor: 3.267

6.  Evaluation of serum arabinitol as a diagnostic test for candidiasis.

Authors:  C L Wells; M S Sirany; D J Blazevic
Journal:  J Clin Microbiol       Date:  1983-08       Impact factor: 5.948

7.  Simultaneous determination of arabinitol and mannose by gas-liquid chromatography in experimental candidiasis.

Authors:  L de Repentigny; R J Kuykendall; E Reiss
Journal:  J Clin Microbiol       Date:  1983-06       Impact factor: 5.948

8.  Estimations of serum arabinitol for diagnosing invasive candidosis.

Authors:  A G Deacon
Journal:  J Clin Pathol       Date:  1986-08       Impact factor: 3.411

9.  Diagnosis of invasive candidiasis in patients with and without signs of immune deficiency: a comparison of six detection methods in human serum.

Authors:  G J Platenkamp; A M Van Duin; J C Porsius; H J Schouten; P E Zondervan; M F Michel
Journal:  J Clin Pathol       Date:  1987-10       Impact factor: 3.411

10.  A permease encoded by STL1 is required for active glycerol uptake by Candida albicans.

Authors:  Gerald Kayingo; António Martins; Rachael Andrie; Luisa Neves; Cândida Lucas; Brian Wong
Journal:  Microbiology (Reading)       Date:  2009-04-21       Impact factor: 2.777

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.